Your session is about to expire
← Back to Search
Excimer Laser
Topography-guided LASIK for Farsightedness
Phase 3
Waitlist Available
Research Sponsored by Clinical Research Consultants, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Summary
This purpose of this study is to evaluate the safety and effectiveness of a topography-based custom ablation treatment using the ALLEGRETTO WAVE® Eye-Q 400 Hz laser system for treating myopia and hyperopia.
Eligible Conditions
- Farsightedness
- Near-sightedness
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From undefined Phase 3 trial • 212 Patients • NCT010283781%
BSCVA loss of 2 or more lines
1%
Retinal Detachments
100%
80%
60%
40%
20%
0%
Study treatment Arm
Topography-guided LASIK
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Topography-guided LASIKExperimental Treatment1 Intervention
Topography-guided LASIK for Myopia or Hyperopia
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser
2009
Completed Phase 3
~220
Find a Location
Who is running the clinical trial?
Clinical Research Consultants, Inc.Lead Sponsor
6 Previous Clinical Trials
1,192 Total Patients Enrolled
WaveLight AGIndustry Sponsor
1 Previous Clinical Trials
144 Total Patients Enrolled
Alcon ResearchIndustry Sponsor
731 Previous Clinical Trials
128,697 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger